Drug Trial Radar · NCT00099268
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Last checked: Nov 19, 2026Latest source record: Apr 23, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
747
Actual
Start
Sep 2004
Primary completion
Nov 2008
Study completion Nov 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Orion Corporation, Orion Pharma
- First posted
- Dec 10, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
Conditions
- Parkinson's Disease
Interventions
Carbidopa/levodopa/entacaponeDrug
Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
Immediate release carbidopa/levodopaDrug
Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of DyskinesiaTime frame: Treatment duration for an individual patient varied between a minimum of 134 weeks for those patients recruited last and a maximum of 208 weeks for those patients recruited first
Locations
73 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic
Scottsdale, Arizona
Coastal Neurological Medical Group
La Jolla, California
Keck School of Medicine, Division of Movement Disorders
Los Angeles, California
Reed Neurological Research Center
Los Angeles, California
The Parkinson's Institute
Sunnyvale, California
Molecular NeuroImaging, LLC
New Haven, Connecticut
Parkinson's Disease and Movement Disorder Center
Boca Raton, Florida
University of Miami
Miami, Florida
Charlotte Neurological Service
Port Charlotte, Florida
University of South Florida
Tampa, Florida
Wesley Woods Health Center
Atlanta, Georgia
Medical College of Georgia
Augusta, Georgia
Northwestern University Medical School
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Landon Center on Aging
Kansas City, Kansas
Ochsner Clinic Foundation
New Orleans, Louisiana
Boston University School of Medicine
Boston, Massachusetts
Clinical Neuroscience Center
Southfield, Michigan
Parkinson's Disease and Movement Disorder Center of Albany Medical
Albany, New York
Parkinson's Disease and Movement Disorders Center of Long Island
Commack, New York
Mount Sinai School of Medicine
New York, New York
Columbia University, Neurological Institute
New York, New York
University of Rochester
Rochester, New York
Duke University Medical Center Movement Disorders Center
Durham, North Carolina
Pennsylvania Neurology Institute
Philadelphia, Pennsylvania
NeuroHealth, Inc.
Warwick, Rhode Island
Semmes-Murphey Clinic
Memphis, Tennessee
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
Baylor College of Medicine, Parkinson's Disease Center
Houston, Texas
Wisconsin Institute for Neurologic and Sleep Disorders
Milwaukee, Wisconsin
Novartis Investigative Site
Innsbruck, Austria
Novartis Investigative Site
Antwerp, Belgium
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Kuopio, Finland
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.